We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Will AmSurg's Merger with Envision Healthcare Drive Growth?
Read MoreHide Full Article
On Jul 11, 2016, we issued an updated research report on Nashville, TN-based AmSurg Corp. – a leading operator of single-specialty practice-based ambulatory surgery centers (ASCs). The company develops, acquires and operates practice-based ASCs in partnership with physician practice groups throughout the U.S.
To further expand its footprint in the huge and fast-growing fragmented physician outsourcing market, AmSurg recently agreed to merge in an all-stock deal with Envision Healthcare Holdings, Inc. . This huge tax-free merger of two healthcare industry biggies is expected to create one of the largest providers of physician services in the U.S dealing in specialties including emergency, hospitalist, anesthesia, radiology and pediatric.
Also, the combined enterprise will have an expanded customer base with respect to ambulatory surgery, post-acute care and medical transportation solutions.
Earlier, AmSurg acquired Sheridan Healthcare – a prominent multi-specialty outsourced physician services provider, for a transaction value of $2.35 billion; in Jul 2014 with the same objective to expand its base in the physician outsourcing market. By this buyout AmSurg expects to capture substantial shares in the radiology and emergency medicine services spaces; wherein Sheridan holds a strong position.
ASCs depend upon third-party reimbursement programs, including governmental and private insurance programs, which primarily pays for all of the services rendered to patients. In July, CMS announced the final payment rule for ASCs for the year 2016. Based on this proposed rule, AmSurg expects an average increase of 1% or $2 million in revenue across its specialties.
The calculation of this final rule indicates that AmSurg will see a 0.5% increase ($1 million) in revenues across all specialties in 2016. Surely this surge will benefit AmSurg in days ahead.
On the flip side, AmSurg continues to face escalating operating expenses for the past few quarters, which in turn has been affecting the company’s margin growth. Widespread macroeconomic turmoil as well as constrained hospital spending has the potential to reduce demand for ASCs like AmSurg.
Zacks Rank & Key Picks
Currently AmSurg holds a Zacks Rank #2 (Buy). Some other medical stocks worth considering are Boston Scientific Corp. (BSX - Free Report) , NuVasive, Inc and GW Pharmaceuticals plc . While Boston Scientific and NuVasive sport a Zacks Rank #1 (Strong Buy), GW Pharmaceuticals holds a Zacks Rank #2 (Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days.Click to get this free report >>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Will AmSurg's Merger with Envision Healthcare Drive Growth?
On Jul 11, 2016, we issued an updated research report on Nashville, TN-based AmSurg Corp. – a leading operator of single-specialty practice-based ambulatory surgery centers (ASCs). The company develops, acquires and operates practice-based ASCs in partnership with physician practice groups throughout the U.S.
To further expand its footprint in the huge and fast-growing fragmented physician outsourcing market, AmSurg recently agreed to merge in an all-stock deal with Envision Healthcare Holdings, Inc. . This huge tax-free merger of two healthcare industry biggies is expected to create one of the largest providers of physician services in the U.S dealing in specialties including emergency, hospitalist, anesthesia, radiology and pediatric.
Also, the combined enterprise will have an expanded customer base with respect to ambulatory surgery, post-acute care and medical transportation solutions.
Earlier, AmSurg acquired Sheridan Healthcare – a prominent multi-specialty outsourced physician services provider, for a transaction value of $2.35 billion; in Jul 2014 with the same objective to expand its base in the physician outsourcing market. By this buyout AmSurg expects to capture substantial shares in the radiology and emergency medicine services spaces; wherein Sheridan holds a strong position.
ASCs depend upon third-party reimbursement programs, including governmental and private insurance programs, which primarily pays for all of the services rendered to patients. In July, CMS announced the final payment rule for ASCs for the year 2016. Based on this proposed rule, AmSurg expects an average increase of 1% or $2 million in revenue across its specialties.
The calculation of this final rule indicates that AmSurg will see a 0.5% increase ($1 million) in revenues across all specialties in 2016. Surely this surge will benefit AmSurg in days ahead.
On the flip side, AmSurg continues to face escalating operating expenses for the past few quarters, which in turn has been affecting the company’s margin growth. Widespread macroeconomic turmoil as well as constrained hospital spending has the potential to reduce demand for ASCs like AmSurg.
Zacks Rank & Key Picks
Currently AmSurg holds a Zacks Rank #2 (Buy). Some other medical stocks worth considering are Boston Scientific Corp. (BSX - Free Report) , NuVasive, Inc and GW Pharmaceuticals plc . While Boston Scientific and NuVasive sport a Zacks Rank #1 (Strong Buy), GW Pharmaceuticals holds a Zacks Rank #2 (Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>